10 WAYS MOLECULAR HYDROGEN IS BEING STUDIED IN CANCER RESEARCH
When I originally wrote this article in 2017, most of the molecular hydrogen and cancer discussion was built around cell studies, animal experiments, oxidative stress, apoptosis, angiogenesis, and a relatively small number of human observations.
The research landscape is much broader today.
We now have additional mechanistic studies, human observational studies, randomized supportive-care trials, studies combining H₂ with chemotherapy or immunotherapy, cancer-specific reviews, and a 2023 systematic review devoted specifically to molecular hydrogen in cancer management.
I still think the correct word is promising.
Molecular hydrogen has demonstrated direct anti-tumor activity in multiple experimental models while human research has reported encouraging findings involving quality of life, treatment-related toxicity, immune function, tumor progression, and survival-related outcomes.
At the same time, the human oncology evidence is not yet at the level where H₂ should be described as an established replacement for surgery, chemotherapy, radiation, targeted therapy, immunotherapy, or other standard cancer treatments.
The question I think the evidence supports today is:
Could molecular hydrogen become a useful adjunct within comprehensive cancer care?
I believe that question deserves serious continued investigation.
Originally published December 19, 2017. Updated August 27, 2026.
H2HUBB Takeaway
- The cancer evidence has expanded considerably since 2017. A 2023 systematic review identified 27 eligible studies spanning cell, animal, and patient-based research.
- Direct anti-tumor effects are best established preclinically. H₂ has affected proliferation, apoptosis, migration, invasion, angiogenesis, CD47 signaling, inflammatory pathways, and other tumor-related mechanisms.
- Human research has produced encouraging signals. Studies have reported improvements in quality of life, treatment-related adverse effects, immune-cell exhaustion, tumor-control measures, and survival-associated outcomes.
- Some of the most interesting work involves H₂ as an adjunct. Research has examined H₂ alongside chemotherapy, radiotherapy, targeted therapies, and immune checkpoint treatment.
- H₂ is not established as a stand-alone cancer treatment. The current literature is promising but still needs larger, well-controlled clinical trials before cancer-specific efficacy or dosing standards can be established.
Where Does Molecular Hydrogen and Cancer Research Stand in 2026?
One of the biggest changes since I wrote the original article is that researchers have now attempted to look at the cancer literature collectively rather than as isolated experiments.
2023: 27 Cancer Studies Reviewed
A systematic review published in the Asian Pacific Journal of Cancer Prevention searched Cochrane, PubMed, and Google Scholar for molecular hydrogen and cancer studies.
From 677 initially identified articles, the researchers included 27 studies meeting their eligibility criteria.
The evidence included:
- cell-culture experiments,
- animal studies,
- clinical studies,
- case reports,
- and observational human studies.
Hydrogen gas was the most common administration method, with hydrogen-rich water and hydrogen-rich saline also represented.
The reviewers concluded that H₂ showed promising therapeutic potential both independently and as an adjunct to conventional cancer treatment , while emphasizing the need for additional comprehensive research.
Reviews published since then have continued to describe H₂ as an emerging complementary or adjunctive strategy in oncology.
Importantly, they also continue to identify the same major challenge:
The biological and preclinical evidence is ahead of the large-scale controlled human evidence.
That is the framework I use throughout this article.
I do not want to dismiss compelling early findings simply because every question has not yet been answered.
But I also do not want to present a cell experiment, mouse experiment, uncontrolled clinical cohort, and randomized human trial as though they all provide the same level of evidence.
10 Areas Where Molecular Hydrogen Has Been Studied in Cancer
My original H2Minutes cancer presentation broke the research into ten major areas.
I still think that is a useful teaching framework.
Oxidative Stress
H₂ has been studied for its ability to regulate excessive oxidative stress and redox-sensitive signaling associated with cancer biology.
DNA Protection
Because oxidative DNA damage can contribute to mutagenesis, researchers have investigated whether H₂ can reduce damaging oxidative reactions affecting DNA.
Mutation & Cancer Development
Experimental work has explored whether reduction of excessive oxidative stress could lower somatic mutation or delay certain forms of experimentally induced cancer development.
Tumor-Cell Growth
Multiple cancer models have reported lower proliferation following H₂ exposure.
Cancer-Cell Death
H₂ has activated apoptosis, pyroptosis, AMPK/AIF/caspase pathways, and other cell-death mechanisms in experimental tumors.
Migration & Spread
Research has reported effects involving MMPs, CDC42, angiogenic signaling, migration, invasion, and metastatic traits.
Anti-Cancer Drugs
H₂ has been investigated both for reducing treatment-related injury and, in some models, enhancing anticancer activity.
Radiation
Studies have examined normal-tissue protection, oxidative stress, quality of life, and radiation-associated injury.
Quality of Life
Human studies have reported changes in fatigue, appetite, sleep, pain, gastrointestinal symptoms, and functional status.
Survival & Immune Function
Early human research has connected H₂ with CD8+ T-cell phenotype, mitochondrial function, progression-free survival, and overall survival signals.
1–3. Oxidative Stress, DNA Damage and Cancer Development
The relationship between oxidation and cancer is complicated.
Reactive oxygen species are not universally bad. Cancer cells can use ROS-dependent signaling to support proliferation, mutation, inflammation, angiogenesis, and survival.
At the same time, sufficiently high oxidative stress can also be used therapeutically to kill cancer cells.
This is one reason I would not describe molecular hydrogen today as simply an antioxidant that removes ROS.
The current question is more about redox regulation.
Why Selectivity Matters
H₂ has been investigated for its ability to regulate highly damaging oxidative species and downstream redox-sensitive pathways without behaving like a conventional high-dose antioxidant that indiscriminately eliminates all oxidative signaling.
That distinction is especially important in oncology because cancer cells and normal cells can respond very differently to changes in oxidative state.
Earlier studies also raised the possibility that H₂ could reduce oxidative DNA damage and therefore influence the acquisition of somatic mutations.
In animal work, hydrogen reduced the incidence and delayed the onset of radiation-induced thymic lymphoma.
I consider that cancer-prevention evidence preclinical.
It is interesting mechanistically, but it does not establish that drinking hydrogen water or inhaling H₂ prevents cancer in humans.
4. Molecular Hydrogen Can Suppress Tumor Growth in Experimental Models
This is one of the more consistently reproduced areas of the preclinical literature.
Different studies have reported inhibition of:
- cancer-cell proliferation,
- colony formation,
- tumor growth,
- stem-like tumor behavior,
- and tumor-associated signaling pathways.
Lung Cancer — SMC3
Hydrogen gas inhibited proliferation, migration and invasion in lung-cancer models and suppressed tumor growth in mice, with SMC3 identified as one molecular target.
Lung Cancer — CD47
H₂ reduced growth, migration and invasion in A549 and H1975 lung-cancer cells and suppressed malignant characteristics in an animal tumor model.
Colon Cancer + 5-FU
Hydrogen water improved survival in tumor-bearing mice and enhanced the inhibitory action of 5-fluorouracil against colon-26 cancer cells.
Other Tumor Models
Experimental work has also reported effects in glioblastoma, endometrial cancer, fibrosarcoma, tongue carcinoma, leukemia and other models.
Something From the Original Article That Still Matters
One of the observations that fascinated me years ago was that some hydrogen-rich-water experiments reported greater growth inhibition in cancer cells than in normal cells.
That remains an interesting line of research.
But I would describe it today as tumor-preferential activity demonstrated in particular experimental models, rather than claiming that H₂ universally kills every cancer cell while protecting every healthy cell.
5. Molecular Hydrogen Can Activate Cancer-Cell Death Pathways
Cancer is not simply uncontrolled cell division.
Cancer cells also become unusually good at avoiding the normal biological signals that tell damaged or abnormal cells to die.
One of the most important forms of regulated cell death is apoptosis.
Multiple H₂ studies have reported increased cancer-cell apoptosis.
AMPK / AIF / Caspase-3
In colon-26 cancer research, hydrogen water increased p-AMPK, apoptosis-inducing factor and caspase-3, consistent with activation of cell-death pathways.
STAT3 / Bcl-2
Lung-cancer research has reported suppression of STAT3 and the anti-apoptotic protein Bcl-2, alongside increased markers associated with apoptosis.
PARP / Caspase Signaling
The CD47 lung-cancer study found increased cleaved caspase-3 and cleaved PARP alongside increased apoptosis after H₂ exposure.
Other Regulated Cell Death
More recent research has also investigated pyroptosis, autophagy-apoptosis interactions, and differentiation of cancer stem-like cells.
One of the most interesting things about the cancer literature is that H₂ does not appear to produce one universal biological response. Its effects depend heavily on the condition of the cell and the signaling environment around it.
6. H₂ Has Been Studied for Tumor Migration, Invasion and Angiogenesis
For a cancer to metastasize, tumor cells need to do more than divide.
They must acquire the ability to:
- detach,
- move,
- degrade surrounding tissue barriers,
- invade nearby structures,
- enter circulation,
- survive transit,
- and establish themselves elsewhere.
Several molecular hydrogen studies have targeted parts of this process.
MMP Signaling
Matrix metalloproteinases such as MMP-2 and MMP-9 can participate in degradation of the extracellular matrix and basement membrane.
Earlier hydrogen-rich-water research reported suppression of MMP expression and reduced invasion of human fibrosarcoma cells.
VEGF and Angiogenesis
VEGF—vascular endothelial growth factor—is a major signal used in the formation of new blood vessels.
Earlier electrolyzed hydrogen-rich-water research reported reductions in VEGF-related tumor angiogenesis under experimental conditions.
CDC42 and Cell Motility
The 2020 lung-cancer CD47 study also found that H₂ reduced CDC42, a signaling protein involved in cell movement and metastatic behavior.
That reduction occurred alongside lower migration and invasion in both A549 and H1975 lung-cancer cells.
H₂, CD47 and the Cancer Cell “Don’t-Eat-Me” Signal
This is one of the strongest additions to the article since 2017.
Cancer cells frequently exploit immune-evasion mechanisms.
One of them involves a cell-surface protein called CD47.
CD47 can interact with SIRPα on macrophages and send a “don’t eat me” signal.
High CD47 expression has been associated with multiple cancers and has itself become a target of modern cancer-immunotherapy research.
Hydrogen Down-Regulated CD47 in Lung-Cancer Models
Researchers exposed A549 and H1975 non-small-cell lung-cancer cells to molecular hydrogen and found that H₂ decreased CD47 and CDC42 expression in a concentration-dependent manner.
H₂ treatment also:
- reduced cancer-cell proliferation,
- reduced migration,
- reduced invasion,
- increased apoptosis,
- and increased macrophage-mediated phagocytosis.
When researchers artificially increased CD47 expression, much of hydrogen’s inhibitory effect was weakened.
When CD47 was knocked down, hydrogen’s effects became stronger.
In simple terms, the study suggests that H₂ may help remove part of the molecular camouflage cancer cells use to avoid being engulfed by macrophages.
This was a cell and animal study—not proof that hydrogen inhalation produces the same clinical effect in a person with lung cancer.
But mechanistically, I think CD47 is one of the most interesting cancer findings in the hydrogen literature.
H₂ May Influence T-Cell Exhaustion and Anti-Tumor Immunity
The immune side of hydrogen oncology has also become much more interesting since the original article.
Cytotoxic CD8+ T cells are one of the immune system’s primary tools for recognizing and destroying abnormal cells.
But prolonged exposure to cancer antigens can drive these cells into a dysfunctional state known as T-cell exhaustion.
Exhausted T cells can lose:
- cytotoxic function,
- normal proliferation,
- cytokine production,
- and mitochondrial fitness.
55 Patients With Stage IV Colorectal Cancer
A study involving 55 patients with stage IV colorectal cancer examined CD8+ T-cell phenotypes while patients received chemotherapy and inhaled hydrogen gas for 3 hours per day.
Hydrogen exposure was associated with:
- fewer exhausted terminal PD-1+ CD8+ T cells,
- more active terminal PD-1− CD8+ T cells,
- and better progression-free and overall-survival associations.
The authors proposed that improvement in mitochondrial function may help restore metabolically exhausted T cells.
Hydrogen + Nivolumab in Lung Cancer
Another human study examined 56 patients with lung cancer who were receiving nivolumab, an immune checkpoint inhibitor.
Forty-two received hydrogen gas in addition to nivolumab, while fourteen received nivolumab without hydrogen.
The hydrogen-plus-nivolumab group showed longer overall survival.
Researchers also measured:
- PD-1 and Tim-3 markers on CD8+ T cells,
- terminal T-cell exhaustion,
- and circulating coenzyme Q10 as a marker related to mitochondrial function.
Lower levels of terminal PD-1+Tim-3+ exhausted CD8+ T cells and higher CoQ10 were associated with better outcomes.
Why I Find This Study Important—And Why I Would Still Be Careful With It
This gives us a plausible biological connection between mitochondrial function → T-cell exhaustion → immune checkpoint response.
But the study was not a large randomized trial.
There were 42 patients in the hydrogen-plus-nivolumab group and only 14 in the nivolumab-only group, so selection bias and other confounding factors remain possible.
I therefore view this as encouraging clinical evidence that deserves confirmation, not proof that hydrogen universally improves immunotherapy outcomes.
7. Molecular Hydrogen Alongside Chemotherapy
This has always been one of the most fascinating parts of the hydrogen cancer literature.
Conventional chemotherapy often relies on mechanisms capable of damaging rapidly dividing cancer cells, but those same treatments can also injure healthy tissue.
The question researchers have asked is:
Can molecular hydrogen reduce treatment-related injury without protecting the tumor from the treatment itself?
5-Fluorouracil
In a colon-26 cancer model, hydrogen-rich water:
- increased cancer-cell apoptosis,
- improved survival in tumor-bearing mice,
- and enhanced the inhibitory effect of 5-fluorouracil.
This was preclinical research, but it directly challenged the idea that hydrogen’s redox effects would necessarily interfere with chemotherapy.
Cisplatin
Preclinical research has also reported that molecular hydrogen reduced cisplatin-associated kidney injury and other toxicity without compromising cisplatin’s anti-tumor activity in the experimental model.
Human mFOLFOX6 Study
Hydrogen Water and Chemotherapy-Related Liver Injury
A randomized single-blind clinical study investigated hydrogen-rich water in colorectal-cancer patients receiving mFOLFOX6 chemotherapy.
A total of 144 patients were randomized, with 136 included in the final analysis.
In the placebo group, chemotherapy was associated with significant increases in several markers of liver injury.
In the hydrogen-water group, those liver-function markers did not significantly worsen from baseline.
The investigators concluded that hydrogen-rich water appeared to alleviate mFOLFOX6-associated liver injury.
I think this is an important part of the cancer story because supporting the patient during treatment may ultimately be a different therapeutic role than directly shrinking a tumor.
8. Molecular Hydrogen and Radiotherapy
Radiation presents a similar biological question.
Radiation treatment intentionally produces cellular damage within the tumor, while unwanted oxidative injury can occur in healthy tissues outside the therapeutic target.
49 Patients Receiving Radiotherapy for Liver Tumors
Researchers studied hydrogen-rich water in 49 patients receiving radiotherapy for malignant liver tumors.
Compared with placebo, hydrogen-rich water:
- reduced blood markers associated with oxidative stress,
- improved quality-of-life scores during radiotherapy,
- and did not significantly change tumor response to radiation.
That last point matters.
In this particular study, hydrogen’s protective effects did not appear to reduce the anti-tumor effectiveness of radiotherapy.
Radiation-Induced Cancer in Animals
Hydrogen has also been studied in a very different radiation context.
In mice, hydrogen reduced the incidence and delayed the development of radiation-induced thymic lymphoma.
That is a prevention-oriented animal model rather than a cancer-treatment trial, so I would keep those two lines of evidence separate.
9. Quality of Life May Be One of the More Clinically Relevant H₂ Outcomes
Cancer research should not only ask whether a tumor becomes larger or smaller.
Patients also care about:
- fatigue,
- pain,
- sleep,
- appetite,
- breathing,
- nausea,
- physical function,
- and the ability to tolerate treatment.
82 Patients With Stage III–IV Cancer
A prospective/retrospective real-world study followed 82 patients with advanced cancer receiving hydrogen inhalation.
After two weeks, the prospectively evaluated patients reported improvements in several measures including:
- fatigue,
- insomnia,
- appetite,
- dyspnea,
- physical function,
- role function,
- and emotional function.
After four weeks, additional improvements were reported in pain and several gastrointestinal symptoms.
These are interesting findings, but this was not a randomized placebo-controlled cancer trial.
Some participants were receiving conventional treatment at the same time, while others were not.
That means we should treat the quality-of-life findings as encouraging observational evidence rather than assume every change was necessarily caused by hydrogen.
10. Tumor Control, Progression and Survival: The Human Signals
This is the area where the language matters the most.
We do have human studies reporting tumor-control and survival-related outcomes.
But most are not yet the kind of large, independently replicated randomized trials needed to establish cancer-treatment efficacy.
82 Advanced-Cancer Patients
Of 80 patients with measurable tumors, the study reported one complete response, 15 partial responses, 30 cases of stable disease and 34 cases of progressive disease after three months.
The resulting reported disease-control rate was 57.5%.
58 Advanced NSCLC Patients
A 2020 study examined hydrogen alone and hydrogen combined with chemotherapy, targeted therapy or immunotherapy.
H₂ groups showed symptom improvement and progression-free-survival signals compared with the control group.
Hydrogen + Nivolumab
Lung-cancer patients receiving hydrogen alongside nivolumab showed longer overall survival than the smaller nivolumab-only comparison group.
NSCLC Brain Metastases
A single patient with metastatic NSCLC experienced substantial reduction of multiple brain metastases after several months of hydrogen-gas monotherapy, with complete disappearance of the brain lesions reported after one year.
The Case Report Is Fascinating—But It Is Still One Patient
The brain-metastasis case is one of the most dramatic reports in the hydrogen oncology literature.
But a case report cannot tell us how often the same response would occur in other patients.
There was no randomized comparison group, and one extraordinary response cannot establish expected treatment efficacy.
I think the correct response is not to ignore it.
The correct response is: this deserves controlled follow-up research.
A Practical Look at the Human Evidence
When I separate the human studies from the laboratory research, this is how I currently view the evidence.
Supportive Care
Randomized studies provide evidence that hydrogen-rich water may help reduce some treatment-associated oxidative injury and improve selected quality-of-life outcomes.
Immune Function
Human studies have reported changes in exhausted CD8+ T-cell populations, active T-cell populations, CoQ10 and related mitochondrial markers.
Tumor Control
Observational studies and case reports have reported partial responses, stable disease and other tumor-control outcomes, but stronger controlled confirmation is needed.
Survival
Some human cohorts report progression-free or overall-survival associations, but non-randomized designs make causal interpretation difficult.
My current position at H2HUBB is that the human evidence is sufficiently interesting to justify serious oncology research, especially as an adjunct—but not sufficiently definitive to call molecular hydrogen an established cancer treatment.
What H₂ Exposure Protocols Have Actually Been Used in Cancer Studies?
This is an area where I want to make an important distinction.
A research protocol tells us what investigators used.
It does not automatically establish an optimal treatment prescription for every person with cancer.
3 Hours Per Day
The 55-patient colorectal-cancer study used hydrogen-gas inhalation for 3 hours daily alongside chemotherapy.
4–5 Hours Per Day
The 58-patient NSCLC study used H₂ inhalation for approximately 4–5 hours per day over several months.
Multi-Hour Exposure
Several Chinese and Japanese oncology reports used multi-hour daily inhalation rather than short 10–30 minute sessions.
No Cancer-Specific Standard
Hydrogen-rich-water studies have used a variety of concentrations, volumes and preparation methods. There is currently no validated universal hydrogen-water dose specifically for cancer treatment.
What Those Inhalation Numbers Do—and Do Not—Mean
The cancer inhalation literature clearly tells us something useful: many of the human studies used repeated multi-hour exposure.
But hours alone do not define the dose.
Actual exposure also depends on:
- H₂ gas output,
- gas composition,
- delivery flow rate,
- cannula versus mask,
- the person’s breathing rate,
- and the resulting inhaled H₂ concentration.
A study using a high-flow hydrogen/oxygen mixture cannot simply be translated into “X hours” on any consumer inhalation machine.
What About Hydrogen Water?
At H2HUBB, we commonly reference approximately 1–3 mg H₂/day as a practical research-informed consumer target based on the amount of molecular hydrogen administered across a broad range of human hydrogen-water studies.
Approximately 1–15 mg/day represents a broader research-informed range encountered across human hydrogen-water research and today’s higher-performing consumer market.
Those are general hydrogen-water research reference ranges.
They are not established cancer-treatment doses.
Learn How Hydrogen Inhalation Exposure Is Evaluated
H2HUBB’s Hydrogen Inhalation Therapy Guide explains H₂ flow rate, inhaled H₂ concentration, pure-hydrogen and oxyhydrogen systems, delivery methods, safety considerations and the differences between machine output and actual human exposure.
What Are the Biggest Limitations in Hydrogen Cancer Research?
There is enough positive evidence here that I think dismissing molecular hydrogen would be premature.
But there are several weaknesses that the field needs to solve.
Small Human Studies
Several of the most interesting oncology studies involve dozens—not hundreds or thousands—of participants.
Non-Randomized Designs
Some survival and tumor-control findings come from observational cohorts where selection bias and confounding cannot be excluded.
Mixed Cancer Types
Cancer is not one disease. Results from colorectal cancer, NSCLC, liver cancer or a mouse tumor model cannot automatically be generalized to every malignancy.
Different H₂ Exposures
Studies have used hydrogen gas, hydrogen-rich water, saline, high H₂ concentrations, low concentrations, different flow rates and dramatically different durations.
Adjunct vs. Monotherapy
Many human participants were also receiving chemotherapy, immunotherapy, targeted therapy or radiotherapy, making hydrogen’s independent contribution difficult to isolate.
Independent Replication
Several influential clinical reports come from a relatively small number of research groups. Independent multicenter replication would strengthen confidence considerably.
What I Want to See Next
- larger randomized controlled trials,
- cancer-specific protocols rather than mixed cohorts,
- clear reporting of H₂ flow and inhaled H₂ concentration,
- dose-response research,
- standardized treatment duration,
- tumor and immune biomarkers before and after H₂,
- independent replication across research centers,
- and trials designed around specific conventional therapies.
The question is no longer whether molecular hydrogen can influence cancer biology in experimental systems. It clearly can. The bigger question now is how much of that biology translates into reproducible clinical benefit in specific human cancers.
My Updated H2HUBB Position on Molecular Hydrogen and Cancer
When I first covered this subject, the mechanisms were what excited me.
VEGF.
MMPs.
oxidative stress.
apoptosis.
DNA protection.
chemotherapy toxicity.
Those concepts are still part of the story.
But the modern story is bigger.
We can now add:
- CD47 immune evasion,
- macrophage phagocytosis,
- CDC42 and metastatic behavior,
- STAT3/Bcl-2 survival signaling,
- T-cell exhaustion,
- PD-1 and Tim-3,
- mitochondrial function,
- CoQ10,
- checkpoint immunotherapy,
- and human quality-of-life and progression data.
That is meaningful scientific progress.
I think molecular hydrogen’s most compelling potential in oncology may ultimately come from its ability to work on both sides of the cancer problem.
Reduce Tumor Fitness
Experimental evidence suggests H₂ can influence proliferation, survival signaling, apoptosis, invasion, migration, angiogenesis and immune-evasion pathways.
Support the Host
Human research suggests potential effects on treatment tolerance, oxidative stress, quality of life, immune-cell function, mitochondrial fitness and T-cell exhaustion.
From our position at H2HUBB, molecular hydrogen does not need to replace conventional oncology to become clinically valuable. If it can help weaken tumor-supporting biology, improve immune competence, reduce treatment burden, or improve quality of life alongside effective cancer care, that would already be important.
Important Cancer Safety Note
Cancer is a serious and highly individualized group of diseases.
Molecular hydrogen should not be used as a reason to delay, discontinue or replace oncology evaluation or treatment that has demonstrated clinical benefit.
Anyone considering H₂ while receiving chemotherapy, radiotherapy, immunotherapy, targeted therapy or another cancer treatment should discuss the plan with the treating oncology team.
The exposure schedules described above are research protocols, not individualized medical prescriptions.
Explore Molecular Hydrogen Research Directly
H2HUBB’s Research Library is designed to help consumers, clinicians, researchers and industry professionals explore the published molecular-hydrogen literature rather than relying on isolated marketing claims.
Watch the Original H2Minutes Cancer Episode
This article grew out of one of my earlier H2Minutes deep dives: CANCER vs. Molecular Hydrogen — Episode 26.
The video walks through the ten areas that originally shaped this article. The research has expanded since it was filmed, which is why I wanted this updated article to show both where the discussion began and where the evidence stands today.
Frequently Asked Questions
Is molecular hydrogen a proven cancer treatment?
Molecular hydrogen has demonstrated substantial experimental anti-tumor activity and encouraging early human findings, but it is not currently established as a replacement for standard cancer treatment.
Human studies still need larger randomized and independently replicated trials to determine its effectiveness for specific cancers and treatment combinations.
Does molecular hydrogen kill cancer cells?
In experimental cancer models, H₂ has increased apoptosis and other regulated cell-death pathways while decreasing proliferation in multiple cancer-cell types.
Those results are strongest in cell and animal studies and should not be interpreted as proof that a particular consumer H₂ protocol will kill a human tumor.
Can hydrogen affect cancer spread?
Preclinical studies have reported reduced migration and invasion and changes involving MMPs, VEGF, CDC42 and other pathways involved in metastatic behavior.
The 2020 lung-cancer CD47 study specifically found lower migration and invasion in A549 and H1975 cells after H₂ exposure.
What is CD47 and why is it important?
CD47 is a cell-surface protein that can communicate a “don’t eat me” signal to macrophages.
Cancer cells can overexpress CD47 to reduce immune clearance. Experimental lung-cancer research found that H₂ lowered CD47, increased macrophage phagocytosis and reduced several malignant characteristics.
Can molecular hydrogen help exhausted T cells?
Human studies in advanced colorectal and lung cancer have reported changes in exhausted CD8+ T-cell populations after repeated hydrogen inhalation.
Researchers have proposed that improved mitochondrial function, including pathways involving PGC-1α and CoQ10, may contribute to this effect.
Has hydrogen been studied with chemotherapy?
Yes. Preclinical research has examined hydrogen with agents such as cisplatin and 5-fluorouracil.
A randomized human study in colorectal-cancer patients receiving mFOLFOX6 also reported protection of liver-function markers with hydrogen-rich water.
Has hydrogen been studied during radiotherapy?
Yes. A randomized placebo-controlled study involving 49 patients receiving radiotherapy for liver tumors found improved quality of life and lower oxidative-stress measures with hydrogen-rich water.
Importantly, tumor response to radiation was not significantly different between the hydrogen and placebo groups in that study.
What hydrogen inhalation protocols have cancer studies used?
Several human cancer studies used multi-hour daily exposure. Examples include approximately 3 hours/day in a stage IV colorectal-cancer study and approximately 4–5 hours/day in an advanced NSCLC study.
These are descriptions of research protocols rather than universal treatment recommendations.
Actual delivered exposure depends on H₂ output, flow, gas composition, delivery interface, breathing rate and inhaled H₂ concentration.
How much hydrogen water should someone with cancer drink?
There is currently no established cancer-specific optimal hydrogen-water dose.
H2HUBB commonly references approximately 1–3 mg H₂/day as a general research-informed consumer target and approximately 1–15 mg/day as a broader range encountered across human hydrogen-water research.
Those ranges are not cancer-treatment prescriptions.
Should molecular hydrogen replace standard cancer treatment?
No. The current evidence does not support abandoning proven oncology treatments in favor of molecular hydrogen.
I think the strongest current research question is H₂’s potential role as an adjunct—particularly its effects on tumor biology, treatment tolerance, immune function and quality of life.
References & H2HUBB Resources
- H2HUBB Molecular Hydrogen Research Library
- H2HUBB Hydrogen Inhalation Therapy Guide
- Molecular Hydrogen Therapy Methods
- Mohd Noor MNZ, Alauddin AS, Wong YH, et al. A Systematic Review of Molecular Hydrogen Therapy in Cancer Management. Asian Pacific Journal of Cancer Prevention. 2023;24(1):37–47. View Study
- Zhou W, Zhang J, Chen W, et al. Prospects of molecular hydrogen in cancer prevention and treatment. Journal of Cancer Research and Clinical Oncology. 2024;150:170. View Review
- Meng J, Liu L, Wang D, Yan Z, Chen G. Hydrogen gas represses the progression of lung cancer via down-regulating CD47. Bioscience Reports. 2020;40(4):BSR20192761. DOI: 10.1042/BSR20192761. View on PubMed
- Wang D, Wang L, Zhang Y, Zhao Y, Chen G. Hydrogen gas inhibits lung cancer progression through targeting SMC3. Biomedicine & Pharmacotherapy. 2018;104:788–797. View on PubMed
- Akagi J, Baba H. Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis. Oncology Reports. 2019;41(1):301–311. DOI: 10.3892/or.2018.6841. View on PubMed
- Akagi J, Baba H. Hydrogen gas activates coenzyme Q10 to restore exhausted CD8+ T cells, especially PD-1+Tim3+ terminal CD8+ T cells, leading to better nivolumab outcomes in patients with lung cancer. Oncology Letters. 2020;20(5):258. DOI: 10.3892/ol.2020.12121. View on PubMed
- Chen JB, Kong XF, Lv YY, et al. “Real world survey” of hydrogen-controlled cancer: a follow-up report of 82 advanced cancer patients. Medical Gas Research. 2019;9(3):115–121. DOI: 10.4103/2045-9912.266985. View Study
- Chen JB, Kong XF, Mu F, et al. Hydrogen therapy can be used to control tumor progression and alleviate the adverse events of medications in patients with advanced non-small-cell lung cancer. Medical Gas Research. 2020;10(2):75–80. DOI: 10.4103/2045-9912.285560. View on PubMed
- Chen J, Mu F, Lu T, Du D, Xu K. Brain Metastases Completely Disappear in Non-Small Cell Lung Cancer Using Hydrogen Gas Inhalation: A Case Report. OncoTargets and Therapy. 2019;12:11145–11151. DOI: 10.2147/OTT.S235195. View on PubMed
- Runtuwene J, Amitani H, Amitani M, et al. Hydrogen-water enhances 5-fluorouracil-induced inhibition of colon cancer. PeerJ. 2015;3:e859. DOI: 10.7717/peerj.859. View on PubMed
- Kang KM, Kang YN, Choi IB, et al. Effects of drinking hydrogen-rich water on the quality of life of patients treated with radiotherapy for liver tumors. Medical Gas Research. 2011;1:11. DOI: 10.1186/2045-9912-1-11. View on PubMed
- Yang Q, Ji G, Pan R, Zhao Y, Yan P. Protective effect of hydrogen-rich water on liver function of colorectal cancer patients treated with mFOLFOX6 chemotherapy. Molecular and Clinical Oncology. 2017;7(5):891–896. DOI: 10.3892/mco.2017.1409. View on PubMed
- Jin J, Yue L, Du M, et al. Molecular Hydrogen Therapy: Mechanisms, Delivery Methods, Preventive, and Therapeutic Application. MedComm. 2025;6(5):e70194. DOI: 10.1002/mco2.70194. View Review
- H2Minutes — CANCER vs. Molecular Hydrogen, Episode 26